Axe Compute Inc.

We are a knowledge-driven company focused on applying artificial intelligence (“AI”) to support the discovery and development of optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. We use AI and our proprietary biobank of 150,000 tumor samples, categorized by tumor type, to provide actionable insights about drug compounds to improve the drug discovery process and increase the probability of drug compound success. We also create and develop tumor-specific 3D cell culture models mimicking the physiological environment of human tissue, enabling better-informed decision-making during drug development. Our suite of solutions supports oncology drug development from early discovery to clinical trials.

Current securities

1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 2, 2026
2. 4 filingOct 5, 2026
3. Entry into a Material Definitive Agreement · Regulation FD DisclosureOct 5, 2026
4. Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of AssetsSep 17, 2026
5. 4 filingSep 9, 2026